NCT05814523: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) |
|
|
| Withdrawn | 3 | 70 | Europe, RoW | Ganaxolone, Placebo, Standard of care | Marinus Pharmaceuticals | Refractory Status Epilepticus | 08/24 | 08/24 | | |